Efgartigimod for Consolidation Therapy in gMG

Inclusion Criteria

• •1. Age ≥18 years, male or female.
• •2. Diagnosis of myasthenia gravis (MG) based on the following:
• •1. Typical clinical features of MG.
• •2. At least one of the following:
• •Seropositive for anti-AChR antibodies (confirmed by reliable assay). Abnormal neuromuscular transmission on electrophysiological testing (e.g., RNS or SFEMG).
• •Positive neostigmine test or documented response to cholinesterase inhibitors.
• •3. MGFA classification II-IV at consolidation baseline.
• •4. Seropositive for anti-AChR antibodies (required for enrollment).
• •5. Hospitalized for myasthenic crisis (MC) in the acute exacerbation and completed one treatment cycle of efgartigimod: acute exacerbation definition: Presence of MC warning signs (new or worsening within 2 weeks): Bulbar symptoms: Dysphagia, choking, weak cough, dysarthria. Respiratory symptoms: Dyspnea, respiratory muscle weakness. Generalized weakness: Head drop, jaw weakness, facial weakness. One treatment cycle of efgartigimod: 10 mg/kg IV, once weekly for 4 doses.
• •6. ≥2-point improvement in MG-ADL score from acute exacerbation baseline by Day 4 of efgartigimod treatment.
• •7. Willing and able to provide written informed consent before study participation.